VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

rMVA- AHS-VP2
Vaccine Information
  • Vaccine Ontology ID: VO_0004758
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Preparation: Recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2) (Castillo-Olivares et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Vaccination Protocol: The mice were vaccinated by the intra-peritoneal route on days 0 and 28 with 107 pfu of MVA-VP2 per mouse (Castillo-Olivares et al., 2011).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The mice were subsequently challenged on day 35 with 106 pfu of AHSV-4 (Castillo-Olivares et al., 2011).
  • Efficacy: All of the MVA-VP2 vaccinated animals were also protected from clinical signs and were completely healthy until the end of the study period (Castillo-Olivares et al., 2011).
References
Castillo-Olivares et al., 2011: Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PloS one. 2011; 6(1); e16503. [PubMed: 21298069].